de ProShare Advisors Acadia Pharmaceuticals ACAD Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 606 k | Vender |
23,970
-3,227
| -12% | -USD 71 k | ﹤0.01% | 980 |
|
|
2026
Q1 | USD 605 k | Vender |
27,197
-4,481
| -14% | -USD 107 k | ﹤0.01% | 970 |
|
|
2025
Q4 | USD 846 k | Comprar |
31,678
+2,215
| +8% | +USD 52.9 k | ﹤0.01% | 875 |
|
|
2025
Q3 | USD 629 k | Vender |
29,463
-4,553
| -13% | -USD 108 k | ﹤0.01% | 994 |
|
|
2025
Q2 | USD 734 k | Vender |
34,016
-1,753
| -5% | -USD 32.6 k | ﹤0.01% | 929 |
|
|
2025
Q1 | USD 594 k | Vender |
35,769
-5,811
| -14% | -USD 106 k | ﹤0.01% | 1001 |
|
|
2024
Q4 | USD 763 k | Comprar |
41,580
+9,164
| +28% | +USD 148 k | ﹤0.01% | 1034 |
|
|
2024
Q3 | USD 499 k | Comprar |
32,416
+5,790
| +22% | +USD 96.6 k | ﹤0.01% | 1138 |
|
|
2024
Q2 | USD 433 k | Vender |
26,626
-6,957
| -21% | -USD 112 k | ﹤0.01% | 1053 |
|
|
2024
Q1 | USD 621 k | Comprar |
33,583
+3,048
| +10% | +USD 75.5 k | ﹤0.01% | 968 |
|
|
2023
Q4 | USD 956 k | Comprar |
30,535
+4,082
| +15% | +USD 97.5 k | ﹤0.01% | 765 |
|
|
2023
Q3 | USD 551 k | Comprar |
26,453
+169
| +0.6% | +USD 4.59 k | ﹤0.01% | 877 |
|
|
2023
Q2 | USD 630 k | Comprar |
26,284
+887
| +3% | +USD 19.7 k | ﹤0.01% | 855 |
|
|
2023
Q1 | USD 478 k | Vender |
25,397
-3,465
| -12% | -USD 66 k | ﹤0.01% | 925 |
|
|
2022
Q4 | USD 459 k | Comprar |
28,862
+1,993
| +7% | +USD 31.2 k | ﹤0.01% | 1001 |
|
|
2022
Q3 | USD 440 k | Vender |
26,869
-1,139
| -4% | -USD 18.4 k | ﹤0.01% | 951 |
|
|
2022
Q2 | USD 395 k | Vender |
28,008
-13,722
| -33% | -USD 256 k | ﹤0.01% | 1049 |
|
|
2022
Q1 | USD 1.01 M | Vender |
41,730
-10,009
| -19% | -USD 242 k | ﹤0.01% | 923 |
|
|
2021
Q4 | USD 1.21 M | Vender |
51,739
-689
| -1% | -USD 13.9 k | ﹤0.01% | 936 |
|
|
2021
Q3 | USD 871 k | Vender |
52,428
-11,630
| -18% | -USD 224 k | ﹤0.01% | 950 |
|
|
2021
Q2 | USD 1.56 M | Comprar |
64,058
+39,719
| +163% | +USD 897 k | ﹤0.01% | 811 |
|
|
2021
Q1 | USD 628 k | Vender |
24,339
-2,279
| -9% | -USD 100 k | ﹤0.01% | 1294 |
|
|
2020
Q4 | USD 1.42 M | Vender |
26,618
-783
| -3% | -USD 38.9 k | 0.01% | 741 |
|
|
2020
Q3 | USD 1.13 M | Comprar |
27,401
+668
| +2% | +USD 28.8 k | 0.01% | 692 |
|
|
2020
Q2 | USD 1.3 M | Vender |
26,733
-3,095
| -10% | -USD 149 k | 0.01% | 642 |
|
|
2020
Q1 | USD 1.26 M | Vender |
29,828
-21,426
| -42% | -USD 883 k | 0.01% | 555 |
|
|
2019
Q4 | USD 2.19 M | Vender |
51,254
-2,329
| -4% | -USD 101 k | 0.01% | 605 |
|
|
2019
Q3 | USD 1.93 M | Vender |
53,583
-3,218
| -6% | -USD 97.6 k | 0.01% | 600 |
|
|
2019
Q2 | USD 1.52 M | Vender |
56,801
-8,894
| -14% | -USD 227 k | 0.01% | 645 |
|
|
2019
Q1 | USD 1.76 M | Comprar |
65,695
+4,195
| +7% | +USD 98 k | 0.01% | 625 |
|
|
2018
Q4 | USD 994 k | Vender |
61,500
-4,960
| -7% | -USD 96.3 k | 0.01% | 704 |
|
|
2018
Q3 | USD 1.38 M | Vender |
66,460
-1,313
| -2% | -USD 20.7 k | 0.01% | 693 |
|
|
2018
Q2 | USD 1.04 M | Comprar |
67,773
+7,596
| +13% | +USD 135 k | 0.01% | 815 |
|
|
2018
Q1 | USD 1.35 M | Vender |
60,177
-9,386
| -13% | -USD 260 k | 0.01% | 719 |
|
|
2017
Q4 | USD 2.1 M | Vender |
69,563
-1,682
| -2% | -USD 53.8 k | 0.01% | 593 |
|
|
2017
Q3 | USD 2.68 M | Comprar |
71,245
+6,600
| +10% | +USD 215 k | 0.02% | 502 |
|
|
2017
Q2 | USD 1.8 M | Vender |
64,645
-2,165
| -3% | -USD 64.5 k | 0.02% | 586 |
|
|
2017
Q1 | USD 2.3 M | Vender |
66,810
-14,556
| -18% | -USD 514 k | 0.02% | 522 |
|
|
2016
Q4 | USD 2.35 M | Comprar |
81,366
+2,678
| +3% | +USD 70.8 k | 0.03% | 502 |
|
|
2016
Q3 | USD 2.5 M | Vender |
78,688
-8,511
| -10% | -USD 289 k | 0.04% | 428 |
|
|
2016
Q2 | USD 2.83 M | Vender |
87,199
-8,397
| -9% | -USD 281 k | 0.04% | 372 |
|
|
2016
Q1 | USD 2.67 M | Vender |
95,596
-144
| -0.2% | -USD 3.14 k | 0.04% | 369 |
|
|
2015
Q4 | USD 3.41 M | Comprar |
95,740
+8,409
| +10% | +USD 296 k | 0.04% | 363 |
|
|
2015
Q3 | USD 2.89 M | Vender |
87,331
-2,866
| -3% | -USD 119 k | 0.04% | 378 |
|
|
2015
Q2 | USD 3.78 M | Vender |
90,197
-5,733
| -6% | -USD 222 k | 0.05% | 339 |
|
|
2015
Q1 | USD 3.13 M | Comprar |
95,930
+12,962
| +16% | +USD 446 k | 0.04% | 423 |
|
|
2014
Q4 | USD 2.63 M | Comprar |
82,968
+466
| +0.6% | +USD 13.2 k | 0.03% | 492 |
|
|
2014
Q3 | USD 2.04 M | Vender |
82,502
-15,947
| -16% | -USD 373 k | 0.03% | 708 |
|
|
2014
Q2 | USD 2.22 M | Vender |
98,449
-42,427
| -30% | -USD 886 k | 0.03% | 672 |
|
|
2014
Q1 | USD 3.43 M | Comprar |
140,876
+95,783
| +212% | +USD 2.42 M | 0.04% | 420 |
|
|
2013
Q4 | USD 1.13 M | Vender |
45,093
-30,368
| -40% | -USD 716 k | 0.02% | 948 |
|
|
2013
Q3 | USD 2.07 M | Comprar |
75,461
+58,622
| +348% | +USD 1.23 M | 0.05% | 383 |
|
|
2013
Q2 | USD 306 k | Comprar |
+16,839
| Nuevas | +USD 232 k | 0.01% | 1712 |
|
Otros fondos que tienen ACAD en su cartera
BBA
Posición de ProShare Advisors en ACAD: resumen de T2 2026
ProShare Advisors redujo su participación en Acadia Pharmaceuticals (ACAD) en 12% durante T2 2026, al vender acciones por un valor estimado de USD 71 k, y conservó 23,970 acciones valuadas en USD 606 k. La posición representa ﹤0.01% de la cartera y ocupa el puesto #980.
ProShare Advisors reportó por primera vez una posición en ACAD en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. La posición alcanzó su máximo de USD 3.78 M en T2 2015. Al cierre de T2 2026, 354 fondos que sigue Wall St. Rank mantienen una posición en ACAD.
- Al cierre de T2 2026, ProShare Advisors tenía 23,970 acciones de Acadia Pharmaceuticals con un valor de USD 606 k.
- ProShare Advisors vendió 3,227 acciones de Acadia Pharmaceuticals en T2 2026, por un valor estimado de USD 71 k.
- Acadia Pharmaceuticals representó ﹤0.01% de la cartera de ProShare Advisors en T2 2026 y fue su posición número 980.
- ProShare Advisors reportó por primera vez una posición en Acadia Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- La posición de ProShare Advisors en Acadia Pharmaceuticals alcanzó su máximo de USD 3.78 M en T2 2015.
- Al cierre de T2 2026, 354 fondos que sigue Wall St. Rank tenían Acadia Pharmaceuticals en cartera.
Según el Informe 13F de ProShare Advisors correspondiente a T2 2026, presentado el 11 ago 2026.